Mechanism
Native human kisspeptin is a 54-amino-acid peptide (kisspeptin-54), produced by neurons in the arcuate nucleus and anteroventral periventricular nucleus of the hypothalamus. Cleaved fragments — kisspeptin-14, kisspeptin-13, and most clinically interesting kisspeptin-10 — retain biological activity through the C-terminal residues that bind the kisspeptin receptor (KISS1R, formerly GPR54).
Kisspeptin’s role in reproductive endocrinology:
- Hypothalamic kisspeptin neurons fire in pulsatile patterns
- Kisspeptin binding to KISS1R on GnRH neurons drives GnRH secretion
- GnRH stimulates pituitary LH and FSH release
- LH/FSH stimulates gonadal steroidogenesis and gametogenesis
This places kisspeptin upstream of GnRH, making it the master regulator of the reproductive axis. Loss-of-function KISS1R mutations cause idiopathic hypogonadotropic hypogonadism (clinical phenotype: failure to enter puberty, low LH/FSH, low gonadal steroids).
Kisspeptin signaling is also modulated by metabolic status (low energy availability suppresses kisspeptin, explaining hypothalamic amenorrhea in low-body-weight athletes), stress, and sex steroids (negative and positive feedback loops).
The clinical interventions exploit this upstream position:
- IVF ovulation trigger: Kisspeptin can replace hCG to trigger LH surge and ovulation, with potentially lower ovarian hyperstimulation syndrome (OHSS) risk
- Hypothalamic amenorrhea: Pulsatile kisspeptin can restore reproductive function in hypothalamic causes of amenorrhea
- HSDD: Kisspeptin has effects on sexual arousal pathways in the brain (parallel to but distinct from oxytocin)
Half-life is short (~30 minutes for kisspeptin-10 IV) — clinical use typically involves IV infusions or repeated subcutaneous dosing.
What the evidence shows
IVF ovulation trigger:
Multiple Phase 2 trials (notably Abbara et al at Imperial College London, 2015 onward) have shown kisspeptin-54 as effective for triggering ovulation in IVF cycles, with substantially lower OHSS rates than hCG. The mechanism is mechanistically clean — kisspeptin causes a physiologic LH surge rather than the supraphysiologic and prolonged hCG-induced response that drives OHSS. Phase 3 trials are in development.
Hypothalamic amenorrhea (Jayasena et al, J Clin Invest 2014): Pulsatile kisspeptin-54 restored ovulation in women with HA. Small population, but mechanistically consistent with the upstream-regulator role.
Sexual desire / HSDD: Imperial College group’s work (Comninos et al, multiple publications) shows kisspeptin enhances sexual arousal responses in both sexes via central neural mechanisms. Phase 2 trials in HSDD ongoing.
Male fertility: Some interest in using kisspeptin to stimulate gonadotropin secretion in hypogonadotropic hypogonadism — has been studied but not advanced to widespread clinical use.
Why we hold at Investigational: The translational science is real and the development arc is active, but no Phase 3 trial has read out. We expect IVF or HSDD applications to be the most likely first approval pathways, with potential timing in 2027–2029.
Dosing literature
Trial protocols use:
- IVF trigger: Single-dose kisspeptin-54 (typically 6.4 nmol/kg subcutaneous or IV)
- Hypothalamic amenorrhea: Pulsatile kisspeptin-54 (subcutaneous, every 90 minutes for several days)
- HSDD studies: Continuous IV infusion at variable rates during fMRI/behavioral testing
Approved dosing does not exist because no indication is approved. Gray-market sale of “kisspeptin” or “kisspeptin-10” exists but is uncommon — the molecule is short-acting and requires clinical infrastructure for the protocols studied.
Risks and adverse events
In published clinical trials:
- Generally well-tolerated short-term acute profile
- Mild headache, occasional nausea
- Transient hot flushes or warmth (consistent with brief LH surge)
- Injection site reactions
Theoretical concerns:
- Long-term effects of chronic kisspeptin agonism are uncharacterized — most clinical use has been single-dose or short courses
- Effects on women trying to avoid conception or men with hormone-sensitive conditions need to be considered
- Reproductive endocrine effects are by design — patients need careful counseling about reproductive implications
Quality concerns:
Gray-market “kisspeptin-10” preparations exist but the market is small and verification standards are particularly poor for short-acting peptides without clinical established protocols. Most legitimate access is through clinical trial enrollment.
Regulatory status
| Region | Status | Notes |
|---|---|---|
| United States | Not approved | Phase 2 trials ongoing for IVF and HSDD applications |
| European Union | Not approved | Phase 2 trials ongoing |
| United Kingdom | Not approved | Active research at Imperial College London is among the most advanced globally |
| All other markets | Not approved |
Where to get it
The legitimate access path is enrolling in an active clinical trial. The Imperial College London group (Waljit Dhillo’s lab) has been the leading translational center; multiple US academic medical centers have followed.
We do not route readers to gray-market sources. Kisspeptin’s clinical use cases (IVF trigger, HA management) require clinical infrastructure that gray-market product simply can’t provide. (See How we make money.)
References (selected)
- Abbara A et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab 2015. PubMed
- Jayasena CN et al. Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers. J Clin Endocrinol Metab 2013.
- Comninos AN et al. Kisspeptin modulates sexual and emotional brain processing in humans. *J
Quick Facts
| Also Known As | Kisspeptin, Metastin, KISS1-54, KP-54 |
|---|---|
| Sequence | YNWNSFGLRF-NH2 (Kisspeptin-10 decapeptide amide is the bioactive core; the full 54-aa sequence is often represented by its one-letter code, but the bioactive C-terminal decapeptide is standard: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2). |
| Molecular Formula | C258H401N79O78 |
| Molecular Weight | 5857 Da |
| PubChem CID | 71306396 |
Research Parameters
| Half-Life | The half-life of kisspeptin-54 in circulation is relatively short. In human studies, the bioactive kisspeptin-10 fragment has a reported half-life of approximately 4-5 minutes following intravenous administration. |
|---|---|
| Stability | Lyophilized kisspeptin peptides are typically stable for at least 12-24 months when stored at -20°C, protected from light and moisture. After reconstitution in sterile solvent, the solution should be aliquoted and stored at -20°C or colder to minimize degradation; stability after reconstitution is often cited as several weeks when frozen, but it is recommended to use it promptly. Specific stability data for reconstituted kisspeptin-54 is limited. |
| Solubility | Recommended reconstitution solvent is sterile bacteriostatic water or sterile 0.9% sodium chloride (normal saline). Acetic acid or acetic acid/water solutions (e.g., 0.1% acetic acid) are sometimes used for enhanced solubility in research settings. |
| Vial Size | 2 mg |
| Storage (Lyophilized) | -20°C or below, protected from light and moisture. For long-term storage, -80°C is recommended. |
| Storage (Reconstituted) | Aliquot and store at -20°C or below. Avoid repeated freeze-thaw cycles. Use within a few weeks. For short-term use, may be stored at 2-8°C for up to 24-48 hours. |
| Typical Research Dose | In human research using kisspeptin-10: 0.1 - 10.0 mcg/kg body weight per bolus injection. A common research dose is 1.6 mcg/kg. |
| Cycle Parameters | Research protocols vary widely. For diagnostic testing, a single subcutaneous or intravenous bolus is standard. For therapeutic exploration in infertility, protocols have used daily subcutaneous injections (e.g., 6.4 mcg/kg) for several days to weeks, or continuous intravenous infusion. |
| Amino Acid Count | 16 |
Mechanism of Action
Kisspeptin-54 exerts its effects primarily through binding and activation of its cognate G-protein coupled receptor, GPR54 (also known as Kiss1R). This receptor is highly expressed on GnRH neurons in the hypothalamus. Upon binding, kisspeptin activates the Gq/11 signaling pathway, leading to phospholipase C activation, inositol trisphosphate (IP3) production, and intracellular calcium mobilization. This depolarizes GnRH neurons, triggering the pulsatile secretion of GnRH into the hypophyseal portal system.
Hypothalamic-Pituitary-Gonadal (HPG) Axis Activation: Kisspeptin neurons in the arcuate and anteroventral periventricular nuclei integrate metabolic, hormonal (e.g., sex steroids, leptin), and environmental signals. They project to and directly stimulate GnRH neurons via Kiss1R. The resulting GnRH pulses drive the pituitary secretion of LH and FSH, which then act on the gonads to stimulate steroidogenesis and gametogenesis.
Negative and Positive Feedback: Kisspeptin neurons are key mediators of sex steroid feedback. Estradiol and testosterone exert negative feedback on kisspeptin expression in the arcuate nucleus, modulating pulse frequency. In females, a subset of kisspeptin neurons in the anteroventral periventricular nucleus mediates the pre-ovulatory estrogen-positive feedback, generating the GnRH/LH surge necessary for ovulation.
Metabolic Integration: Kisspeptin neurons also act as metabolic sensors, linking nutritional status to reproductive competence. They express receptors for metabolic hormones like leptin and insulin, allowing them to suppress reproductive function during states of energy deficit.
Research Applications
Reproductive Endocrinology: Kisspeptin-54 is a pivotal research tool for probing the fundamental neurobiology of the HPG axis. Studies use it to investigate the mechanisms of puberty onset, the generation of GnRH pulses, and the neurocircuitry of sex steroid feedback. It has been administered to humans in research settings to potently and safely stimulate LH and FSH release, providing a diagnostic tool for assessing hypothalamic function.
Fertility Disorders: Research explores kisspeptin as a potential therapeutic for conditions characterized by low GnRH activity, such as congenital hypogonadotropic hypogonadism and functional hypothalamic amenorrhea. Clinical studies have demonstrated its ability to induce ovulation in women with infertility and to stimulate testosterone production in men with low LH pulses.
Contraception and Reproductive Health: Investigating kisspeptin antagonists or modulators of kisspeptin signaling is an active area for developing novel, non-steroidal contraceptives. Understanding kisspeptin's role may also lead to treatments for polycystic ovary syndrome (PCOS) and disorders of puberty timing.
Cancer Research: Given its origin as a metastasis suppressor, research continues into the role of KISS1/kisspeptin signaling in various cancers, including breast, ovarian, and prostate cancer, exploring its potential anti-metastatic properties.
Safety & Side Effects
In controlled human research studies, kisspeptin administration (typically as kisspeptin-10) has been generally well-tolerated. Reported side effects are mild and transient. The most common is local erythema or mild discomfort at the injection site following subcutaneous administration. Flushing and feelings of warmth have been occasionally reported with IV bolus doses. No serious adverse events directly attributable to kisspeptin have been reported in these clinical trials. Theoretical concerns based on its mechanism include the potential for over-stimulation of the reproductive axis, but this has not been a significant issue in short-term studies. Long-term safety data in humans is not available. Anecdotal side effects from non-clinical use are not documented in the scientific literature.
Dosage Information
This information is derived from published human and animal research studies only and does not constitute medical advice. In human clinical research, kisspeptin-10 (the bioactive fragment) is more commonly used than the full 54-amino acid peptide. Typical research doses of kisspeptin-10 in human studies range from 0.1 to 10.0 mcg/kg body weight, administered as a single intravenous (IV) or subcutaneous (SC) bolus injection to stimulate gonadotropin release. Continuous IV infusion protocols have also been used in research settings at lower hourly rates (e.g., 1.5-4.0 mcg/kg/hr). The frequency is typically a single administration for diagnostic tests or repeated injections/infusions over several days in therapeutic exploration studies. Duration of administration in research protocols varies from single doses to multi-day regimens.
References
Ohtaki, T., et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 411, 613-617 (2001).
Seminara, S.B., et al. The GPR54 gene as a regulator of puberty. New England Journal of Medicine 349, 1614-1627 (2003).
de Roux, N., et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proceedings of the National Academy of Sciences 100, 10972-10976 (2003).
Dhillo, W.S., et al. Kisspeptin-54 stimulates the hypothalamic-pituitary-gonadal axis in human males. Journal of Clinical Endocrinology & Metabolism 90, 6609-6615 (2005).
Jayasena, C.N., et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. Journal of Clinical Investigation 124, 3667-3677 (2014).
Skorupskaite, K., George, J.T., & Anderson, R.A. The kisspeptin-GnRH pathway in human reproductive health and disease. Human Reproduction Update 20, 485-500 (2014).
Uenoyama, Y., et al. Central mechanism controlling pubertal onset in mammals: A triggering role of kisspeptin. Frontiers in Endocrinology 10, 312 (2019).